| Methods |
Participants |
Intervention |
Outcomes |
Notes |
| Number of study arms |
Primary site (prostate vs breast vs multiple myeloma vs lung vs combination) |
For each of intervention arm/active control arm: name of bisphosphonate (etidronate, clodronate, pamidronate, others) |
Which of the following pain measure outcome can be extracted from the study: |
Oxford Quality Scale score (Jadad) |
| Study design (blind/ open/active controls) |
Whether patients have to have bone metastases or not at the time of enrolment (bone mets vs bone mets not required) |
Route of administration |
Mean pain score pre and post treatment |
Number and reason of dropouts |
| If crossover study, duration of washout period |
Whether patients have to have pain prior to study enrolment (pain or pain not required) |
Dose schedule |
Proportion of patients with pain reduction |
Other notes |
| Pain measurement tool used |
Other interventions in study arm (chemotherapy / hormonal therapy/ others) |
Duration of therapy |
P value only for a pain measure |
|
| Pain score expressed by : patient /physician/ unknown |
Performance status measure (life expectancy / others) |
|
Not reported as an endpoint |
|
| Criteria of response for pain. This is only applicable if proportion of patients reponding is an outcome measure. Not specified infers that this is an outcome measure by definition not provided, not applicable infers that this is not an outcome measure used. |
Other specifications for inclusion/exclusion |
|
Which of the following analgesics change can be extracted from the data: |
|
| Analgesic measurement tool used |
|
|
proportion with analgesic reduction |
|
| Criteria of response for analgesic |
|
|
Others |
|
| |
|
|
Adverse effects for control, and study arm |
|
